We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EVR:NYSEEvercore Inc. Analysis

Data as of 2026-04-01 - not real-time

$301.03

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Evercore is trading well below its discounted cash‑flow fair value, creating a notable valuation gap. The stock sits beneath its 20‑day and 50‑day simple moving averages, signaling a bearish technical backdrop, yet the MACD histogram has turned positive, hinting at short‑term momentum. RSI hovers near the mid‑range, suggesting neither extreme overbought nor oversold conditions. Volume trends are decreasing, which could limit rapid price moves but also reflects a quieter market environment. Fundamentals remain strong, with revenue growth exceeding 30% and operating margins above 24%, positioning the firm as a high‑margin player in capital markets. The dividend yield of roughly 1% is supported by a modest payout ratio and ample cash reserves, indicating sustainability.
Looking ahead, the combination of robust earnings growth, a solid ROE near 30%, and an attractive upside potential of about 25% underpin a bullish outlook. The high beta and elevated 30‑day volatility flag heightened price swings, but the company’s US‑centric operations limit geographic and currency exposures. Analysts collectively rate the stock as a “buy,” and the target median price sits above current levels, reinforcing the upside narrative. Given the undervalued status, strong cash flow generation, and resilient business model, the investment case leans toward buying and holding through multiple horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Positive MACD histogram suggests emerging momentum
  • Price remains above key support, limiting downside
  • Valuation gap provides immediate upside potential

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth and high operating margins
  • Undervalued relative to DCF fair value
  • Sustainable dividend adds total‑return appeal

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Robust ROE and capital‑markets franchise
  • Forward EPS growth indicates expanding earnings
  • Valuation discrepancy suggests multi‑year upside

Key Metrics & Analysis

Financial Health

Revenue Growth32.20%
Profit Margin15.35%
P/E Ratio21.4
ROE30.07%
ROA13.44%
Debt/Equity49.79
P/B Ratio5.7
Op. Cash Flow$1.3B
Industry P/E16.5

Technical Analysis

TrendBearish
RSI54.2
Support$265.87
Resistance$316.58
MA 20$282.85
MA 50$316.91
MA 200$317.42
MACDBullish
VolumeDecreasing
Fear & Greed Index77.71

Valuation

Fair Value$824.29
Target Price$376.90
Upside/Downside25.20%
GradeUndervalued
TypeGrowth
Dividend Yield1.13%

Risk Assessment

Beta1.77
Volatility47.13%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.